Wordt geladen...
Gemtuzumab Ozogamicin for Treatment of Acute Myeloid Leukemia
INTRODUCTION: Gemtuzumab ozogamicin (GO) is an antibody-drug conjugate consisting of a monoclonal antibody targeting CD33 linked to a cytotoxic derivative of calicheamicin. Despite the known clinical efficacy in relapsed/refractory acute myeloid leukemia (AML), GO was withdrawn from the market in 20...
Bewaard in:
| Gepubliceerd in: | Expert Rev Clin Pharmacol |
|---|---|
| Hoofdauteurs: | , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6661897/ https://ncbi.nlm.nih.gov/pubmed/29787320 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/17512433.2018.1478725 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|